Published on
Updated on
This year alone, the American Cancer Society estimates almost 2 million new cancer cases will occur in the United States, and at least 25% of cases may be fatal. That’s why MU Bond Life Sciences Center principal investigator Paul de Figueiredo and his team at the University of Missouri are working to lower these numbers through the Synthetic Programmable bacteria for Immune-directed Killing in tumor Environments (SPIKEs) project.
The goal of the project is to build an inexpensive and safe therapeutic using bacteria that can recruit and regulate tumor-targeting immune cells to help the body fight cancer cells without the side effects of traditional medications.
To read more, visit showme.missouri.edu.